Nuclear Imaging Market Size Analysis, Growth Trends & Forecast to 2034

Nuclear Imaging Market Overview

The global nuclear imaging market was valued at USD 13.5 billion in 2026 and is projected to reach USD 23.9 billion by 2034, expanding at a CAGR of 7.8% during the forecast period. The nuclear imaging market consists of innovative technologies for the purpose of conducting imaging diagnostics using small quantities of radioactive tracers to determine the functioning of organs, metabolic processes in tissues, and disease progression. Such technologies include various types of imaging such as SPECT and PET, in addition to hybrid techniques that utilize both functional and structural imaging. Nuclear imaging has a very important place in the diagnostics, staging, and treatment planning of cancer, cardiovascular, neurodegenerative, and other chronic diseases. Growth drivers of the market include constant innovation in imaging technologies, expansion in the area of radiopharmaceuticals, precision medicine adoption, and disease diagnosis.

Nuclear Imaging Market Drivers and Opportunities

Rising Prevalence of Chronic Diseases Is Driving Market Growth

 The increased burden of chronic diseases in the world, such as cancer, cardiovascular conditions, neurological diseases, and infections, is among the significant drivers behind the use of nuclear imaging technologies. Nuclear imaging allows early diagnosis of diseases, disease staging, treatment response monitoring, and accurate disease diagnosis, which helps make therapeutic decisions and achieve better results for patients. Moreover, the increased focus on personalized and precision medicines further drives the use of PET scans, SPECT, and hybrid imaging equipment in hospitals and imaging centers.

The increased prevalence of chronic diseases further underscores the importance of advanced imaging diagnostics. For example, it has been reported by the World Health Organization (WHO) that an estimated 1.3 million new cases of HIV infection and 10.7 million new cases of tuberculosis were reported in 2024. Though the rate of occurrence of both of these diseases has dropped in comparison to previous years, there is still a large number of people who require disease diagnostics, disease monitoring, and treatment evaluation, thus increasing the use of imaging technologies. Furthermore, the increased burden of cancer, cardiovascular diseases, and neurological disorders is expected to further boost the demand for nuclear imaging technology.

Advancements in Hybrid Imaging and Radiopharmaceuticals Fueling Market Expansion

Innovations in the field of hybrid imaging technology and radiopharmaceuticals are bringing about a lot of growth potential in the nuclear imaging industry. Innovations in PET/CT, SPECT/CT, and PET/MRI are contributing to improved imaging, increased accuracy of diagnoses, and providing comprehensive anatomic and functional imaging in one examination. Simultaneously, innovations in radiotracers are helping the nuclear imaging market expand its applications to oncology, cardiology, neurology, among others, for better diagnosis, disease staging, and treatment planning. The market players are also driving innovation through the introduction of next-generation imaging devices. For example, in January 2026, Siemens Healthineers was granted FDA approval to launch the Biograph One, the second generation of the PET/MR imaging device, capable of providing imaging of the anatomy, physiology, and metabolism of organs. This technology innovation is making the process of imaging easier and improving the confidence of clinicians, leading to increased adoption of hybrid imaging devices and thus promoting growth in the global nuclear imaging market.

Growing Adoption of Precision Medicine and Theranostics Presents Significant Opportunities

There are substantial opportunities for the nuclear imaging industry due to the increasing use of precision medicine and theranostics. Molecular imaging modalities have become more prevalent as a means to detect biomarkers specific to diseases, study tumor biology, choose the right treatment option, and assess the efficacy of the treatment. PET and SPECT imaging have played a crucial part in the process of developing personalized therapy approaches because of the unique capabilities they offer. The increased utilization of theranostics technology, which integrates diagnostic imaging along with targeted radionuclide treatment, is further adding to the demand for high-end nuclear imaging technologies and radiopharmaceuticals, especially in oncology. The application of radiotracers to find out patients who could be treated by targeted therapies and monitor the efficacy of treatments in real time is growing. The increased adoption of radioligand therapies to treat prostate cancer, neuroendocrine cancers, and other cancers, along with ongoing research into the development of new radiopharmaceuticals and precision oncology, will continue to expand the scope of nuclear imaging applications. The trend towards personalizing patient care and value-based care in healthcare systems across the world is anticipated to boost the growth of the nuclear imaging market in the coming years.

Nuclear Imaging Market Scope

Nuclear Imaging Market Report Segmentation Analysis

The global nuclear imaging market industry analysis is segmented by product, by application, by end user, and by region.

Single Photon Emission Computed Tomography (SPECT) Systems Segment Is Expected to Dominate the Nuclear Imaging Market During the Forecast Period

The segment of SPECT systems is anticipated to lead the nuclear imaging market during the forecast period due to their extensive clinical use, low cost, and numerous diagnostic applications. SPECT systems are widely utilized in the areas of cardiology, oncology, neurology, and orthopedics for assessment of organ function, disease detection at the early stage, and treatment evaluation. Their use with several proven radiopharmaceuticals, together with the ability of SPECT imaging in various hospitals and diagnostic centers, will contribute to their large procedure volume. Furthermore, the rising use of hybrid SPECT/CT devices and improved image quality and detector technologies, along with higher demand for functional imaging, have added another layer to the strength of the growth of this segment. In comparison with PET imaging systems, SPECT provides a more cost-effective imaging alternative and enjoys increased availability of radiotracers and installed systems. It is anticipated that these factors will help the SPECT systems segment sustain its dominant position in the nuclear imaging market.

Oncology Segment Is Expected to Lead the Nuclear Imaging Market by Application

Oncology is anticipated to dominate the nuclear imaging market throughout the forecasted period due to the growing prevalence of cancer worldwide, along with the increasing use of molecular imaging technology for the early detection, diagnosis, staging, and monitoring of the disease. Nuclear imaging technologies such as PET and SPECT offer functional and metabolic data, which in turn supplement conventional imaging technologies to facilitate early tumor detection. The increased use of hybrid imaging modalities such as PET/CT and PET/MRI and the emergence of innovative radiotracers have been contributing further towards the use of nuclear imaging for precision oncology. Also, the rise in the adoption of the theranostic approach involving the use of imaging to select patients who are candidates for targeted radionuclide therapy has led to a greater need for advanced nuclear imaging technology. Consistent developments in cancer treatment infrastructure, development of radiopharmaceuticals, and personalized medicine are anticipated to aid in the dominance of the oncology segment within the nuclear imaging market.

Diagnostic Imaging Centers Segment Is Expected to Dominate the End User Segment

It is estimated that the segment of diagnostic imaging centers would continue to lead the nuclear imaging market in terms of market share over the forecast period on account of increased demand for advanced diagnostic procedures, rising chronic ailments, and preference for specialized outpatient imaging facilities. Diagnostic imaging centers possess advanced PET, SPECT, PET/CT, and SPECT/CT devices, which allow quality imaging for various clinical applications like oncology, cardiology, and neurology, among others, along with faster scheduling and efficient pricing options.

Additionally, an increase in the number of independent imaging centers, a rise in investment for advanced imaging technologies, and adoption of hybrid imaging systems and new radiopharmaceuticals are factors contributing to segment growth. An increasing number of diagnostic imaging procedures, along with the need for early detection of diseases, are anticipated to ensure dominance of diagnostic imaging centers in the global nuclear imaging market over the forecast period.

The following segments are part of an in-depth analysis of the global nuclear imaging market:

Nuclear Imaging Market Share Analysis by Region

North America is projected to hold the largest share of the global nuclear imaging market over the forecast period  

The market share of North America will be dominant in the global nuclear imaging market in the forecast period due to the developed healthcare infrastructure, higher prevalence of advanced imaging techniques such as PET, SPECT, PET/CT, and PET/MRI; and also because of the prevalence of cancer, cardiovascular, and neurological diseases. Good reimbursement policies, availability of radiopharmaceuticals, and leading players in medical imaging and research institutes in this region have contributed to the development of this market.

Besides this, growing investments in molecular imaging, personalized medicine, theranostics, and radiopharmaceuticals will assist in the growth of the market. Moreover, innovation in product range, approval process, and increase in the use of nuclear imaging technology in diagnosing and treating diseases will also contribute to the growth of this market.

Nuclear Imaging Market Competition Landscape Analysis

The nuclear imaging market is dominated by top players in the medical imaging and radiopharmaceutical industries, concentrating on developing technologies like PET, SPECT, PET/CT, SPECT/CT, and PET/MRI for better diagnosis and efficiency. Players are consolidating their position in the market with innovation in products, collaborations, mergers and acquisitions, regulatory clearances, geographical expansion, and research & development. In addition to that, the increasing popularity of hybrid imaging technology, precision medicine, theranostics, and new radiopharmaceuticals provides numerous growth avenues in the nuclear imaging market. 

Global Nuclear Imaging Market Recent Developments News:

●        In April 2026 – Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative positron emission tomography (PET) radiopharmaceuticals, announced that nine abstracts featuring the latest data on its growing portfolio and pipeline were presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting.

●        In March 2025 - The Medicines and Healthcare Products Regulatory Agency (MHRA) approved trofolastat (RoTecPSMA), the first prostate-specific membrane antigen (PSMA)-targeting product authorized for use with technetium-99m to detect cancerous lesions in men with prostate cancer.

●        In March 2025  - TLX007-CDx was approved by the FDA for PSMA-PET scanning in adult male patients with prostate cancer with suspected metastasis or suspected recurrence.

●        In January 2025 - Lantheus Holdings, Inc., the leading radiopharmaceutical-focused company committed to enabling clinicians to find, fight, and follow disease to deliver better patient outcomes, announced a definitive agreement to acquire Life Molecular Imaging Ltd. in an all-cash transaction consisting of an upfront payment of USD 350 million and up to an additional USD 400 million in potential earn-out and milestone payments. Life Molecular, a subsidiary of Life Healthcare Group Holdings Ltd., is dedicated to advancing novel Positron Emission Tomography (PET) radiopharmaceutical diagnostics.

The Global Nuclear Imaging Market is dominated by a few large companies, such as

●        Blue Earth Diagnostics

●        Bracco Imaging S.p.A.

●        Canon Medical Systems

●        Cardinal Health

●        Cubresa Inc.

●        Curium Pharma

●        DDD-Diagnostic A/S

●        Digirad Health

●        Eckert & Ziegler

●        FUJIFILM Healthcare

●        GE HealthCare

●        Jubilant Radiopharma

●        Lantheus Holdings

●        Mediso Ltd.

●        Philips Healthcare

●        Shimadzu Corporation

●        Siemens Healthineers

●        Spectrum Dynamics Medical

●        Telix Pharmaceuticals

●        United Imaging Healthcare

●        Other Prominent Players